Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Irinotecan for Recurrent Malignant Gliomas
NCT00268359Phase 2Completed
- Sponsor
- Duke University
- Start
- May 2005
- Primary completion
- Aug 2006
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in malignant glioma, sponsored by Duke University. Started May 2005; status: completed.
02
Drugs
bevacizumab
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT00268359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00268359.